<DOC>
	<DOCNO>NCT00764972</DOCNO>
	<brief_summary>This phase IB/II trial sorafenib , new tyrosine kinase inhibition multiple gene active renal cancer , plus vinorelbine , chemotherapy agent active breast cancer . The investigator combine 2 drug order determine investigator increase activity vinorelbine metastatic breast cancer patient . Patients measurable metastatic breast cancer without previous chemotherapy metastatic disease eligible protocol . They treat 2 different dose level sorafenib order determine tolerable dose .</brief_summary>
	<brief_title>Phase IB/II Trial Combining Vinorelbine With Sorafenib First-Line Treatment Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Women affect histologically prove metastatic breast cancer . Tumor susceptible therapy trastuzumab , define FISH negative HER2 amplification immunohistochemistry 01+ HER2 expression . Female , age ≥ 18 . Documented measurable disease appropriate radiologic image accord RECIST criterion ( see Appendix E ) . Lesions previously irradiate area consider measurable disease , unless progression document postradiation . ECOG performance status 01 ( see Appendix B ) Life expectancy &gt; 6 month . Adequate bone marrow function , indicate : Hemoglobin ≥ 90 g/L Neutrophils ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Adequate renal function , indicate serum creatinine ≤1.5 time upper limit normal and/or Creatinine Clearance calculate &gt; 50 % low normal limit , estimate ≥ 50 ml/min ( Appendix C ) . Adequate liver function , indicate : bilirubin ≤ 1.5 time upper normal limit ; AST ALT ≤ 2 time upper normal limit . Left ventricular ejection fraction ( LVEF ) ≥50 % measure either multigated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . No therapy breast cancer 4 week precede therapy start . Women childbearing potential must use adequate contraception negative pregnancy test time enrollment . Patient able understand give write informed consent . Patients locally advance breast cancer stage IIIb . Presence nonmeasurable disease . Previous ( neo ) adjuvant chemotherapy vinorelbine . Any previous antiangiogenic therapy . Any previous chemotherapy metastatic breast cancer . Previous hormonal treatment radiotherapy metastatic disease allow . Radiotherapy , chemotherapy hormonal therapy breast cancer last 4 week prior start study treatment . Major surgery within 4 week first study treatment , minor surgery ( include placement access device ) within 7 day therapy start . Presence lifethreatening disease central nervous system localization . Evidence HER2 positive breast cancer , define FISHpositive amplification score 3+ immunohistochemistry . Any possibly active primary tumor , except basal cell carcinoma skin , carcinoma situ cervix . Clinically significant hepatic disease respect hepatitis B , hepatitis C , cirrhosis liver disease . Uncontrolled bacterial , viral fungal infection . Previous history ischemic disease . Patients previous history thromboembolic event , document risk factor thrombotic disease cancer . History gross hemorrhage within past 6 month ( e.g. , hemoptysis hematuria require medical intervention ) . Uncontrolled hypertension . Other serious medical condition , uncontrolled cardiac disease , severe pulmonary disease , uncontrolled diabetes . Patient exhibit confusion disorientation . Any condition ( medical , social , psychological , geographical ) would prevent adequate followup . Patient pregnant , breastfeeding , unwilling use adequate contraception . Failure give inform consent .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>To evaluate use sorafenib add vinorelbine chemotherapy , find dos two drug safely combine</keyword>
</DOC>